Safety and clinical outcomes of orelabrutinib, lenalidomide plus sintilimab for relapsed/refractory diffuse large B-cell lymphoma
Orelabrutinib, lenalidomide plus sintilimab demonstrated promising efficacy and a manageable safety profile in Chinese patients with R/R DLBCL.
Authors
- Yongfen Huang
- Hailiang Chu
- Hao Xu (ORCID: https://orcid.org/0000-0002-6946-5186)
- Yuqing Miao
- Wei Sang (ORCID: https://orcid.org/0000-0002-1170-7074)
- Xiaoyong Wang (ORCID: https://orcid.org/0000-0001-6048-6100)
- Yuexin Cheng (ORCID: https://orcid.org/0009-0008-7040-4314)
- Lingling Wang (ORCID: https://orcid.org/0000-0003-3576-1080)
- Danning Xu (ORCID: https://orcid.org/0000-0003-2958-1825)
- Chunling Wang
Institutions
- Xuzhou Medical College (CN)
- Nantong University (CN)
- Huaian First People’s Hospital (CN)
- Affiliated Hospital of Xuzhou Medical College (CN)
- Bozhou People's Hospital (CN)
- Yancheng First People's Hospital (CN)
- Yancheng Third People's Hospital (CN)
- Yancheng Second People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1629224
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47